Agios Pharmaceuticals CEO David Schenkein's 2018 pay jumps 37% to $8.2M
Agios Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 18, 2019
Agios Pharmaceuticals reported fiscal year 2018 executive compensation information on April 18, 2019.
In 2018, five executives at Agios Pharmaceuticals received on average a compensation package of $4.1M, a 36% increase compared to previous year.
Average pay of disclosed executives at Agios Pharmaceuticals
David P. Schenkein, Chief Executive Officer, received $8.2M in total, which increased by 37% compared to 2017. 63% of Schenkein's compensation, or $5.2M, was in option awards. Schenkein also received $508K in non-equity incentive plan, $625K in salary, $1.9M in stock awards, as well as $12K in other compensation.
For fiscal year 2018, the median employee pay was $345,181 at Agios Pharmaceuticals. Therefore, the ratio of David P. Schenkein's pay to the median employee pay was 24 to one.
Andrew Hirsch, Chief Financial Officer, received a compensation package of $3.1M, which increased by 35% compared to previous year. 56% of the compensation package, or $1.7M, was in option awards.
Christopher Bowden, Chief Medical Officer, earned $3.1M in 2018, a 34% increase compared to previous year.
Scott Biller, Chief Scientific Officer, received $3.1M in 2018, which increases by 35% compared to 2017.
Steve Hoerter, Chief Commercial Officer, earned $3.1M in 2018, a 36% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 18, 2019.